ethyl 3-hexylnon-2-enoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 3-hexylnon-2-enoate
• 化学式: C₁₇H₃₂O₂
• 分子量: 268.44
• InChiKey: NEYBYVXMAULVBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  19
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 3-hexylnon-2-enoate 在 10 wt% Pd(OH)2 on carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以95%的产率得到ethyl 3-hexylnonanoate
  参考文献：
  名称：

  WO2021055835A5

  摘要：

  公开号：

  WO2021055835A5
• 作为产物：
  描述：

  2-nonyl-1-ol, diethyl acetal 以 甲苯 为溶剂， 反应 30.0h， 生成 ethyl 3-hexylnon-2-enoate
  参考文献：
  名称：

  通过1,2,4-三唑稳定的烯丙基阴离子合成α，β-不饱和酯，α，β-不饱和γ-内酯和2-烷氧基吡咯的新型合成物。

  摘要：

  1-（1,2,4-三唑-1-基）苯基炔丙基乙基醚11（由苯基炔丙基醛二乙基乙缩醛8和1,2,4-三唑制备）的二价阴离子12（左叉的右叉）烷基卤化物，醛，酮和α，β-不饱和酮，仅得到类型10的γ-取代的烯丙基产物。这些加合物经过温和的原位水解，可方便地合成α，β-不饱和酯9a-c和α，β -不饱和的γ-内酯16、18、20和22。二价阴离子13与亚胺的反应以高收率生成了1,3,4-三取代的2-烷氧基吡咯27、30和31。烷基取代的类似物34经历类似的反应，主要得到γ产物39,40和42以及一小部分α-类似物。

  DOI：

  10.1021/jo961397l

文献信息

• Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
  申请人：ModernaTX, Inc.

  公开号：US11066355B2

  公开（公告）日：2021-07-20

  The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

  本公开的特征是新型脂质和涉及新型脂质的组合物。脂质纳米颗粒（如空 LNPs 或负载 LNPs）包括新型脂质以及磷脂、结构脂质和 PEG 脂质等其他脂质。脂质纳米颗粒（如空LNPs或负载LNPs）进一步包括治疗和/或预防剂，如RNA，可用于向哺乳动物细胞或器官输送治疗和/或预防剂，以调节多肽、蛋白质或基因表达等。
• WO2021055833A5
  申请人：——

  公开号：WO2021055833A5

  公开（公告）日：2023-09-26
• BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
  申请人：ModernaTX, Inc.

  公开号：US20210087135A1

  公开（公告）日：2021-03-25

  The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
• CARBONATE CONTAINING LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
  申请人：ModernaTX, Inc.

  公开号：US20220411361A1

  公开（公告）日：2022-12-29

  The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
• [EN] BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS LIPIDIQUES DE QUEUE RAMIFIÉS ET COMPOSITIONS POUR L'ADMINISTRATION INTRACELLULAIRE D'AGENTS THÉRAPEUTIQUES
  申请人：MODERNATX INC

  公开号：WO2021055833A1

  公开（公告）日：2021-03-25

  The application relates to lipids of Formula (A), Formula (B) and Formula (1-1), and to lipid nanoparticles (empty or loaded LNPs) including such a lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.